PREVENT-HD was designed to evaluate the safety and efficacy of rivaroxaban in reducing the risk of major venous and arterial thrombotic events in patients with COVID-19. Over 1200 patients were randomized to receive either rivaroxaban, placebo or standard care for COVID-19.
The study showed that rivaroxaban, prescribed for 35 days in non-hospitalized patients with symptomatic COVID-19 at-risk for thrombosis, did not reduce a composite endpoint of venous and arterial thrombotic events, hospitalisation and death.
Access our full AHA 22 Scientific Coverage here.
Recorded Remotely from Lubbock and Boston, 2022.
Editor: Jordan Rance and Mirjam Boros
Video Specialist: Dan Brent and Oliver Miles